Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

8.580 +0.610 (+7.65%)
Streaming Delayed Price Updated: 11:53 AM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 288,877
Open 8.300
Bid (Size) 8.560 (2)
Ask (Size) 8.580 (5)
Prev. Close 7.970
Today's Range 8.245 - 8.590
52wk Range 7.350 - 13.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
From Alvotech
Via GlobeNewswire

Performance

YTD
-34.8%
-34.8%
1 Month
+5.7%
+5.7%
3 Month
-3.6%
-3.6%
6 Month
+0.6%
+0.6%
1 Year
-31.4%
-31.4%

More News

Read More
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Alvotech's Earnings: A Preview
Via Benzinga
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
From Alvotech
Via GlobeNewswire
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
From Alvotech
Via GlobeNewswire
Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
From Alvotech
Via GlobeNewswire
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
Soho House, GoodRx Holdings, Dayforce And Other Big Stocks Moving Higher On Monday
Via Benzinga
Alvotech SA (NASDAQ:ALVO) Surpasses Q2 2025 Estimates with Strong Revenue and EPS Growth
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
From Alvotech
Via GlobeNewswire
Earnings Scheduled For August 13, 2025
Via Benzinga
Why Is Alvotech Stock Trading Higher On Wednesday?
Via Benzinga
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
From Alvotech
Via GlobeNewswire
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
From Alvotech
Via GlobeNewswire
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
From Alvotech
Via GlobeNewswire
Main Results of 2025 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
From Alvotech
Via GlobeNewswire

Frequently Asked Questions

Is Alvotech - Ordinary Shares publicly traded?
Yes, Alvotech - Ordinary Shares is publicly traded.
What exchange does Alvotech - Ordinary Shares trade on?
Alvotech - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alvotech - Ordinary Shares?
The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market
What is the current price of Alvotech - Ordinary Shares?
The current price of Alvotech - Ordinary Shares is 8.580
When was Alvotech - Ordinary Shares last traded?
The last trade of Alvotech - Ordinary Shares was at 10/14/25 11:53 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.